Sassine leaves Visiomed
By Renate Krelle
Monday, 07 February, 2005
Monday, 07 February, 2005
WA biotech Visiomed (ASX:VSG) has replaced retiring CEO Saliba Sassine with William Dolphin, formerly of New Zealand's SpectraNet and patient monitoring equipment company, SonaMed.
Dolphin, who is to take control in April, will be responsible for moving Visiomed's FDA-cleared asthma device, the Funhaler, into commercial production.
The change is one of several to have occurred at CEO level among Australian biotechs this year.
Related News
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
